(Q40902124)

24 September 2017

1 reference

title

Focal therapy for prostate cancer 1996: maximizing outcome (English)

1 reference

24 September 2017

Carroll PR

1

1 reference

24 September 2017

Presti JC Jr

series ordinal

2

1 reference

24 September 2017

Small E

series ordinal

3

1 reference

24 September 2017

Roach M 3rd

series ordinal

4

1 reference

24 September 2017

language of work or name

English

0 references

publication date

1 March 1997

1 reference

24 September 2017

1 reference

24 September 2017

49

1 reference

24 September 2017

3A Suppl

1 reference

24 September 2017

84-94

1 reference

Ability of preoperative serum prostate-specific antigen value to predict pathologic stage and DNA ploidy. Influence of clinical stage and tumor grade

24 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

Detection of occult micrometastases in the bone marrow of patients with prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: Prognostic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

Reference range for prostate-specific antigen levels after external beam radiation therapy for adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

Correlation of pathologic findings with progression after radical retropubic prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

A multivariable analysis of clinical factors predicting for pathological features associated with local failure after radical prostatectomy for prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

Prostatic cryotherapy: ultrasonographic and pathologic correlation in the canine model

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

US-guided percutaneous cryoablation of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

Critical temperature for skin necrosis in experimental cryosurgery

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

Percutaneous cryoablation of the prostate: preliminary results after 95 procedures

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

Acute toxicity during external-beam radiotherapy for localized prostate cancer: comparison of different techniques.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

Conformal static field radiation therapy treatment of early prostate cancer versus non-conformal techniques: a reduction in acute morbidity

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

Radiotherapy for high grade clinically localized adenocarcinoma of the prostate.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

Defining treatment margins for six field conformal irradiation of localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

The value of nonuniform margins for six-field conformal irradiation of localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

Dose escalation for stage C (T3) prostate cancer: minimal rectal toxicity observed using conformal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

Photon neutron mixed-beam radiotherapy of locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

Photon versus fast neutron external beam radiotherapy in the treatment of locally advanced prostate cancer: results of a randomized prospective trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

Guided brachytherapy for treatment of confined prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

Late rectal bleeding following combined X-ray and proton high dose irradiation for patients with stages T3-T4 prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer: the jury is still out.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

I-125 interstitial implantation for prostate cancer. What have we learned 10 years later?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

A CT-based evaluation method for permanent implants: application to prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

Intermittent endocrine therapy for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

Demonstration of a rational strategy for human prostate cancer gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

Gene therapy approaches in urologic oncology.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

Radioimmunoscintigraphy with 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900174-X

7 January 2021

10.1016/S0090-4295(97)00174-X

Identifiers

DOI

1 reference

24 September 2017

1 reference